Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00471731 · ClinicalTrials.gov registry record
Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure
A clinical trial of Menopause and Turner Syndrome, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 72
- Enrollment target
- 1
- Study location
NCT00471731: Completed study of Menopause and Turner Syndrome, sponsored by National Eye Institute (NEI).
NCT00471731 is a study of Menopause and Turner Syndrome that has completed, run by National Eye Institute (NEI). The registered enrollment target is 72 participants, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00471731, a study of Menopause and Turner Syndrome, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Premature ovarian failure (POF) is known to be associated with an increased risk of ocular surface disease (dry eye), likely due to the reduction of both estrogens and androgens seen in this condition. From preliminary data, we suspect that women with Turners syndrome (45, XO), a genetic abnormality that affects sex hormone levels, are also at increased risk of ocular surface disease. Comparing POF and TS women may allow us to distinguish different mechanisms for ocular surface disease, due to the different etiologies of hormonal (estrogen and androgen) alterations posed by POF and TS.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2007-05-07 |
| Est. Completion | 2014-11-13 |
What the finished NCT00471731 record still lists
NCT00471731 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 9,393-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with Menopause appearing as the primary indexed condition, and to 0 interventions.
NCT00471731 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00471731 about?
NCT00471731 is a clinical study titled "Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure". Premature ovarian failure (POF) is known to be associated with an increased risk of ocular surface disease (dry eye), likely due to the reduction of both estrogens and androgens seen in this condition. From preliminary data, we suspect that women with Turners syndrome (45, XO), a genetic abnormality...
What is the current status of trial NCT00471731?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2007-05-07. Estimated completion is 2014-11-13.
What conditions does trial NCT00471731 study?
This clinical trial studies the following conditions: Menopause, Turner Syndrome, Perimenopause, Ovarian Failure, Premature, Sex Chromosome Aberrations.
Who is sponsoring clinical trial NCT00471731?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00471731 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00471731's enrollment target sits among peer trials
72 27th of 54 higher than 28 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function
RECRUITING
-
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
RECRUITING
-
Apple Women's Health Study
RECRUITING
-
Hot Flashes and Neurovascular Function in Women
RECRUITING · NA
-
Cardiometabolic Consequences of the Loss of Ovarian Function
RECRUITING · Phase 4
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI